Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rare Mutation Increases Both HDL-Cholesterol and Heart Disease Risk

By LabMedica International staff writers
Posted on 20 Mar 2016
Increased risk of atherosclerosis has been attributed to a rare mutation in the gene that encodes the major liver cell receptor for HDL (high-density lipoprotein).

Scavenger receptor class B, type I (SR-BI), which is encoded by the SCARB1 gene, is an integral membrane protein found in numerous cell types, including those in the liver and adrenal glands. More...
It is best known for its role in facilitating the uptake of cholesteryl-esters from HDL in the liver. This process drives the movement of cholesterol from peripheral tissues towards the liver for excretion and is a protective mechanism against the development of atherosclerosis.

Cardiovascular disease investigators at the University of Pennsylvania (Philadelphia, USA) focused on SCARB1 after finding that mice with depleted SCARB1 (SR-BI knockout mice) had markedly elevated HDL-C levels but, paradoxically, increased atherosclerosis. The impact of SR-BI on HDL metabolism and coronary heart disease risk in humans was not clear.

To clarify the link between SCARB1 and HDL-C levels the investigators conducted targeted DNA sequencing of coding regions of lipid-modifying genes in 328 individuals with extremely high plasma HDL-C levels. As a consequence, they identified a homozygote for a loss-of-function variant, in which leucine replaced proline 376 (P376L), in SCARB1. The mutant gene coded for a nonfunctional form of the SR-BI receptor.

The investigators reported in the March 11, 2016, issue of the journal Science that inactive SR-BI blocked HDL-C uptake by liver cells from an individual with two copies of the mutant SCARB1 gene, in induced pluripotent stem cells derived from this individual and converted into liver cells, and in SCARB1 knockout mice. In addition, large population-based studies revealed that subjects who were heterozygous carriers of the P376L variant had significantly increased levels of plasma HDL-C but also an increased risk of coronary heart disease.

“This mutation prevents the receptor from getting to the cell surface where it needs to be situated in order to bind and take up HDL,” said senior author Dr. Daniel J. Rader, professor of genetics at the University of Pennsylvania. “This disruption in the receptor’s job is due to mistakes in its folding and processing during protein synthesis. Our results indicate that some causes of raised HDL actually increase risk for heart disease. This is the first demonstration of a genetic mutation that raises HDL but increases risk of heart disease.”

“The work demonstrates that the protective effects of HDL are more dependent upon how it functions than merely how much of it is present,” said Dr. Rader. “We still have a lot to learn about the relationship between HDL function and heart disease risk. Our results indicate that some causes of raised HDL actually increase risk for heart disease. Eventually we may want to perform genetic testing in persons with high HDL to make sure they do not have mutations—like this one—that raise HDL but does not protect against, or may even increase, risk for heart disease.”

Related Links:
University of Pennsylvania



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.